Clinical research
Over the course of the past year, Novartis has seen significant success with the approval of five drugs that have blockbuster potential and the company sees an additional 25 potential blockbuster drugs in its pipeline.
Shares of France-based Ipsen are down more than 2% on the Euronext Paris exchange after the U.S. Food and Drug Administration placed a partial clinical hold on its investigational treatment for fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO).
FerGene, a gene therapy company formed by Ferring Pharmaceuticals and Blackstone Life Sciences, reported that its Phase III trial of nadofaragene firadenovec (rAd-IFN/Syn3) met its primary endpoint.
Biogen presented full data today on its Alzheimer’s drug aducanumab at the 12th Clinical Trials on Alzheimer’s Disease conference held in San Diego.
The company presented full trial data at the 12th Clinical Trials on Alzheimer’s Disease meeting in San Diego on Wednesday.
“This extraordinary pivotal data confirms voclosporin’s ability to achieve statistically significant improvements in clinically meaningful endpoints for this complex disease, with a comparable safety profile to the current standard of care,” said Neil Solomons, Aurinia’s chief medical officer.
The Phase III failure was certainly a setback for the company as it chased Janssen and its Esketamine-based treatment Spravato for MDD.
First patient enrolled at The University of Kansas Cancer Center in expansion cohort study characterizing the safety, pharmacokinetics and pharmacodynamics of fosciclopirox in bladder cancer patients
The 12th Clinical Trials on Alzheimer’s Disease conference kicks off today. One of the big stories, which will be presented on Thursday, December 5, is detailed results from Biogen’s Phase III clinical trials of aducanumab.
Da Volterra, a clinical-stage biopharmaceutical company developing innovative products to protect the intestinal microbiota, announced the results of DAV132CL-1005, a Phase 1 clinical study which investigated the potential effect of DAV132 on the bioavailability of warfarin or clonazepam, two widely used drugs with narrow therapeutic index.
PRESS RELEASES